Elite in Multiple Sclerosis (MS)

Jeremy C. Hobart

Tamar Science Park, Room N13 ITTC Building, Davy Road, 
Plymouth, ENG, GB 
Elite in Multiple Sclerosis (MS)
Tamar Science Park, Room N13 ITTC Building, Davy Road, 
Plymouth, ENG, GB 
OverviewLocationsClinical Research

Overview

Jeremy Hobart practices in Plymouth, United Kingdom. Mr. Hobart is rated as an Elite expert by MediFind in the treatment of Multiple Sclerosis (MS). His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Hyperhidrosis, and Systemic Mastocytosis.

His clinical research consists of co-authoring 71 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 48 articles and participated in 4 clinical trials in the study of Multiple Sclerosis (MS).

Gender
Male

Locations

Tamar Science Park, Room N13 ITTC Building, Davy Road, Plymouth, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?
ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drug: Cladribine
Study Phase: Phase 2/Phase 3
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Early Highly Effective Therapies Group, Escalation Therapies Group
Study Phase: Phase 4
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability
A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Simvastatin
Study Phase: Phase 3
View 3 Less Clinical Trials

71 Total Publications

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hobart's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile